Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study
Leslie S. Kean(Boston Children's Hospital), Susan DeWolf(Memorial Sloan Kettering Cancer Center), Najla El Jurdi(University of Minnesota), Marcie Riches(Medical College of Wisconsin), Harlan Robins(Adaptive Biotechnologies (United States)), Hany Elmariah(Moffitt Cancer Center), Hemant S. Murthy(University of Florida), Robert R. Jenq(City Of Hope National Medical Center), Lyndsey Runaas(Medical College of Wisconsin), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Saurabh Chhabra(Medical College of Wisconsin), Amin M. Alousi(McGill University), Kristy Applegate(Emmes (United States)), Shernan G. Holtan(University of Minnesota), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Suman R. Das(Fakir Mohan University), Stephanie A. Bien(Fred Hutch Cancer Center), Alison W. Loren(University of Pennsylvania), Mahasweta Gooptu(Harvard University), John E. Levine(Icahn School of Medicine at Mount Sinai), Monzr M. Al Malki(City of Hope), Wael Saber(Medical College of Wisconsin), Sung Won Choi(University of Michigan), Karamjeet Sandhu, Anthony D. Sung(Duke University), Brian C. Shaffer(Memorial Sloan Kettering Cancer Center), Merav Bar(Fred Hutch Cancer Center), Andrew R. Rezvani(Stanford Blood Center), Danielle Scheffey(Adaptive Biotechnologies (United States)), Ami S. Bhatt(Stanford University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Armin Rashidi(University of Minnesota), Catherine Sanders(Adaptive Biotechnologies (United States)), Karilyn Larkin(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mary M. Horowitz(Medical College of Wisconsin), Steven J. Siegel(Boston Children's Hospital), Javier Bolaños‐Meade(Johns Hopkins University), William Clark(Virginia Commonwealth University), Joseph Schmalz(Adaptive Biotechnologies (United States))
Cited by 12
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k